GenSpera G-202 Principal Investigator Presents Phase I Data at Symposium on Molecular Targets and Cancer Therapeutics

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, will present data from the G-202 Phase I clinical trial at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA on Monday, October 21st (http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-and-cancer-therapeutics.aspx). Dr. Mahalingam will present a poster, “A first-in-human phase 1 clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane Antigen (PSMA) activated prodrug, in patients with advanced solid tumors,” in the session from 12:30 – 3:00. Dr. Mahalingam is an oncologist at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC